Abstract | INTRODUCTION: METHODS: Two-hundred ninety-five sera were collected from patients for whom ACPA was ordered and tested for ACPA by QUANTA Lite® CCP 3 (INOVA Diagnostics, Inc., San Diego) and EliA® CCP (CCP, Phadia, Germany). Rheumatoid factor (RF) was determined using Quantex RF(II) (Biokit, Spain). RESULTS: Acceptable qualitative (96.6%, kappa=0.93) and quantitative agreements (Spearman rho=0.77; p<0.0001) were observed between the two ACPA assays. Nine samples were CCP3+/CCP2- and one sample was CCP2+/CCP3-. Of the 9 CCP3+/CCP2- patients, 6 (66.7%) had RA, one patient had ankylosing spondylitis, one osteoarthritis and one psoriatic arthritis. The CCP3-/CCP2+ patient had juvenile RA. At the manufacturer's cut-offs, the sensitivities and specificities were 77.3%/98.1% (CCP2), 81.6%/96.8% (CCP3) and 65.2%/89.6% (RF), respectively. At 98.7% specificity level, the sensitivities in the total cohort were 59.6% (CCP2) and 69.5% (CCP3) while the sensitivities in the RF-negative group were 49.0% (CCP2) and 57.1% (CCP3). In the RF-negative group, sensitivities for patients with a disease duration of ≤ 5years were 38.7% (CCP2) and 51.6% (CCP3). CONCLUSION: Discrimination between RA and non-RA patients was better using CCP3, most pronounced in RF-negative RA.
|
Authors | Andreas Swart, Rufus W Burlingame, Irmgard Gürtler, Michael Mahler |
Journal | Clinica chimica acta; international journal of clinical chemistry
(Clin Chim Acta)
Vol. 414
Pg. 266-72
(Dec 24 2012)
ISSN: 1873-3492 [Electronic] Netherlands |
PMID | 23022338
(Publication Type: Journal Article)
|
Copyright | Copyright © 2012 Elsevier B.V. All rights reserved. |
Chemical References |
- Autoantibodies
- Biomarkers
- Peptides, Cyclic
- cyclic citrullinated peptide
|
Topics |
- Arthritis, Rheumatoid
(diagnosis, immunology)
- Autoantibodies
(blood, immunology)
- Biomarkers
(blood)
- Female
- Humans
- Immunoassay
- Male
- Middle Aged
- Peptides, Cyclic
(blood, immunology)
- Sensitivity and Specificity
|